Home › Research › Biomarkers
Diagnostic performance of plasma p-Tau217, p-Tau181, and p-Tau231 across the Alzheimer's disease continuum: a network meta-analysis
Xiaofen Chen, Tingting Huang, Chao Shi, Shuizhi Xu, Shuwei Fan. Frontiers in aging neuroscience, 2026-06-03
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
A total of 18 high-quality studies comprising 24 independent datasets and 4,736 participants were included. For detecting Aβ pathology, p-tau217 measured by MS (p217_MS) demonstrated the highest diagnostic accuracy (P-score = 0.86), followed by p-tau217 ratio (p217_Ratio) (P-score = 0.78) and automated immunoassays (P-score = 0.67-0.69), all of which significantly outperformed standard p-tau181 immunoassays (P-score = 0.12). Notably, the p-tau217/Aβ 42 ratio on automated platforms provided a significant incremental AUC gain of 0.025 (95% CI: 0.005 to 0.045; I2 = 0%) compared to single-analyte assays, effectively bridging the performance gap with MS. In disease staging, while p-tau231 showed potential in detecting early amyloidosis, p-tau217_MS was superior for identifying advanced Tau-PET pathology (P-score = 0.91) and predicting MCI-to-dementia conversion (P-score = 0.82). Subgroup analyses confirmed consistent performance of p-tau217 across Han Chinese and Western cohorts, and demonstrated the diagnostic potential of serum-based assays as a viable matrix. CONCLUSIONS AND RELEVANCE: Plasma p-tau217, particularly when measured by mass spectrometry or as a ratio on fully automated platforms, offers the highest accuracy for AD diagnosis and staging. While p-tau231 may serve as an early indicator of amyloidosis, p-tau217 is the most robust marker for tau pathology and disease progression. These findings support the integration of automated p-tau217 assays into routine clinical care to streamline patient stratification for disease-modifying therapies. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier (CRD420261327845).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Chen, X., Huang, T., Shi, C., Xu, S., & Fan, S. (2026). Diagnostic performance of plasma p-Tau217, p-Tau181, and p-Tau231 across the Alzheimer's disease continuum: a network meta-analysis. Frontiers in aging neuroscience. https://doi.org/10.3389/fnagi.2026.1834591
Vancouver
Chen X, Huang T, Shi C, Xu S, Fan S. Diagnostic performance of plasma p-Tau217, p-Tau181, and p-Tau231 across the Alzheimer's disease continuum: a network meta-analysis. Frontiers in aging neuroscience. 2026. doi:10.3389/fnagi.2026.1834591. PMID: 42318558.
BibTeX
@article{chen2026-42318558,
author = {Chen, Xiaofen and Huang, Tingting and Shi, Chao and Xu, Shuizhi and Fan, Shuwei},
title = {{Diagnostic performance of plasma p-Tau217, p-Tau181, and p-Tau231 across the Alzheimer's disease continuum: a network meta-analysis}},
journal = {Frontiers in aging neuroscience},
year = {2026},
doi = {10.3389/fnagi.2026.1834591},
pmid = {42318558},
url = {https://doi.org/10.3389/fnagi.2026.1834591}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- A total of 18 high-quality studies comprising 24 independent datasets and 4,736 participants were included.
- For detecting Aβ pathology, p-tau217 measured by MS (p217_MS) demonstrated the highest diagnostic accuracy (P-score = 0.86), followed by p-tau217 ratio (p217_Ratio) (P-score = 0.78) and automated immunoassays (P-score = 0.67-0.69), all of which significantly outperformed standard p-tau181 immunoassays (P-score = 0.12).
- Notably, the p-tau217/Aβ 42 ratio on automated platforms provided a significant incremental AUC gain of 0.025 (95% CI: 0.005 to 0.045; I2 = 0%) compared to single-analyte assays, effectively bridging the performance gap with MS.
- In disease staging, while p-tau231 showed potential in detecting early amyloidosis, p-tau217_MS was superior for identifying advanced Tau-PET pathology (P-score = 0.91) and predicting MCI-to-dementia conversion (P-score = 0.82).
- Subgroup analyses confirmed consistent performance of p-tau217 across Han Chinese and Western cohorts, and demonstrated the diagnostic potential of serum-based assays as a viable matrix.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designsystematic review
- Participants4,736
- Evidence strengthHigh
How this study scored 84/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 47 of the 56 points we could judge it on, which is 84 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in aging neuroscience) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 4,736 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42318558) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 47 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 47 of the 56 points we could judge it on is 84 out of 100. |
| Total | 84 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.